Neuroprotective Effects of Angiotensin Receptor Blockers
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ismail, 2010, Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering, Curr Diab Rep, 10, 32, 10.1007/s11892-009-0081-y
Zanchetti, 2006, Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE)–a review, Blood Press, 15, 71, 10.1080/08037050600771583
Saavedra, 2012, Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders, Clin Sci (Lond), 123, 567, 10.1042/CS20120078
Nelson, 2014, Hypertension and inflammation in Alzheimer’s disease: close partners in disease development and progression!, J Alzheimers Dis, 41, 331, 10.3233/JAD-140024
Richardson, 2014, Impaired renal function and biomarkers of vascular disease in Alzheimer’s disease, Curr Alzheimer Res, 11, 253, 10.2174/1567205011666140131121739
Bugnicourt, 2013, Cognitive disorders and dementia in CKD: the neglected kidney-brain axis, J Am Soc Nephrol, 24, 353, 10.1681/ASN.2012050536
Hasnain, 14, 2014 ( ), Possible role of vascular risk factors in Alzheimer’s disease and vascular dementia, Curr Pharm Des
Pelisch, 2013, RAS inhibition attenuates cognitive impairment by reducing blood- brain barrier permeability in hypertensive subjects, Curr Hypertens Rev, 9, 93, 10.2174/15734021113099990003
Saavedra, 2011, Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications, Psychoneuroendocrinology, 36, 1, 10.1016/j.psyneuen.2010.10.001
Zhou, 2006, AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats, Stroke, 37, 1271, 10.1161/01.STR.0000217404.64352.d7
Lanz, 2010, Angiotensin II sustains brain inflammation in mice via TGF-beta, J Clin Invest, 120, 2782, 10.1172/JCI41709
Batenburg, 2012, (Pro)renin and its receptors: pathophysiological implications, Clin Sci (Lond), 123, 121, 10.1042/CS20120042
Ferrario, 2014, An evolving story of angiotensin-II-forming pathways in rodents and humans, Clin Sci (Lond), 126, 461, 10.1042/CS20130400
Horiuchi, 2012, Regulation of angiotensin II receptors beyond the classical pathway, Clin Sci (Lond), 123, 193, 10.1042/CS20110677
Saavedra, 2012, Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders, Cell Mol Neurobiol, 32, 667, 10.1007/s10571-011-9754-6
Michel, 2013, A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists, Pharmacol Rev, 65, 809, 10.1124/pr.112.007278
Noda, 2012, Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques, Nucl Med Biol, 39, 1232, 10.1016/j.nucmedbio.2012.06.012
Shimizu, 2012, Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3, Nucl Med Biol, 39, 847, 10.1016/j.nucmedbio.2012.01.008
Benicky, 2011, Angiotensin II AT1 receptor blockade ameliorates brain inflammation, Neuropsychopharmacology, 36, 857, 10.1038/npp.2010.225
Benicky, 2009, Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery, Cell Mol Neurobiol, 29, 781, 10.1007/s10571-009-9368-4
Nishimura, 2000, Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors, Brain Res, 871, 29, 10.1016/S0006-8993(00)02377-5
Seltzer, 2004, Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats, Brain Res, 1028, 9, 10.1016/j.brainres.2004.06.079
Charlton, 2008, Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model, Pharm Res, 25, 1531, 10.1007/s11095-008-9550-2
Hawkes, 2009, Parkinson’s disease: the dual hit theory revisited, Ann N Y Acad Sci, 1170, 615, 10.1111/j.1749-6632.2009.04365.x
Obermeier, 2013, Development, maintenance and disruption of the blood-brain barrier, Nat Med, 19, 1584, 10.1038/nm.3407
Danielyan, 2007, Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNF alpha release, Neurochem Res, 32, 1489, 10.1007/s11064-007-9337-6
Pang, 2012, Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes, J Hypertens, 30, 87, 10.1097/HJH.0b013e32834dde5f
Pang, 2012, Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways, J Neuroinflammation, 9, 102, 10.1186/1742-2094-9-102
Sohn, 2013, Antihypertensive drug Valsartan promotes dendritic spine density by altering AMPA receptor trafficking, Biochem Biophys Res Commun, 439, 464, 10.1016/j.bbrc.2013.08.091
Wang, 2014, Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation, Neuropharmacology, 79, 249, 10.1016/j.neuropharm.2013.11.022
Duvernoy, 1983, The vascularization of the human cerebellar cortex, Brain Res Bull, 11, 419, 10.1016/0361-9230(83)90116-8
Ando, 2004, Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats, Stroke, 35, 1726, 10.1161/01.STR.0000129788.26346.18
Ito, 2002, Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist, Stroke, 33, 2297, 10.1161/01.STR.0000027274.03779.F3
Nishimura, 2000, Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats, Stroke, 31, 2478, 10.1161/01.STR.31.10.2478
Villapol, 2012, Candesartan, an angiotensin II AT1-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice, Neuropsychopharmacology, 37, 2817, 10.1038/npp.2012.152
Shigematsu, 1986, Angiotensin II binding sites in the anteroventral-third ventricle (AV3V) area and related structures of the rat brain, Neurosci Lett, 67, 37, 10.1016/0304-3940(86)90204-1
Min, 2012, Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice, Hypertension, 59, 1079, 10.1161/HYPERTENSIONAHA.112.192401
Pelisch, 2011, Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats, Am J Hypertens, 24, 362, 10.1038/ajh.2010.241
Bader, 2010, Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy, Annu Rev Pharmacol Toxicol, 50, 439, 10.1146/annurev.pharmtox.010909.105610
Nap, 2003, AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease, Auton Autacoid Pharmacol, 23, 285, 10.1111/j.1474-8673.2004.00301.x
Tsutsumi, 1991, Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain, Am J Physiol, 261, R209
Diz, 1988, Bidirectional transport of angiotensin II binding sites in the vagus nerve, Hypertension, 11, I139, 10.1161/01.HYP.11.2_Pt_2.I139
Quan, 2007, Brain-immune communication pathways, Brain Behav Immun, 21, 727, 10.1016/j.bbi.2007.05.005
Jaggi, 2011, Exploring the potential of telmisartan in chronic constriction injury-induced neuropathic pain in rats, Eur J Pharmacol, 667, 215, 10.1016/j.ejphar.2011.06.017
Sánchez-Lemus, 2009, Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen, Am J Physiol Regul Integr Comp Physiol, 296, R1376, 10.1152/ajpregu.90962.2008
Fukuda, 2010, Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor, Invest Ophthalmol Vis Sci, 51, 3629, 10.1167/iovs.09-4107
Danielyan, 2010, Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease, Rejuvenation Res, 13, 195, 10.1089/rej.2009.0944
Tsukuda, 2009, Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation, Hypertension, 54, 782, 10.1161/HYPERTENSIONAHA.109.136879
Iadecola, 2013, The pathobiology of vascular dementia, Neuron, 80, 844, 10.1016/j.neuron.2013.10.008
Liu, 2014, The role of inflammasome in Alzheimer’s disease, Ageing Res Rev, 15, 6, 10.1016/j.arr.2013.12.007
Robbins, 2009, The AT1 receptor antagonist, L-158,809, prevents or ameliorates fractionated whole-brain irradiation-induced cognitive impairment, Int J Radiat Oncol Biol Phys, 73, 499, 10.1016/j.ijrobp.2008.09.058
Tota, 2012, Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function, Psychopharmacology (Berl), 222, 185, 10.1007/s00213-012-2639-7
Tota, 2009, Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin, Behav Brain Res, 199, 235, 10.1016/j.bbr.2008.11.044
Wincewicz, 12, 2014 ( ), Angiotensin II AT1 receptor blockade by telmisartan reduces impairment of spatial maze performance induced by both acute and chronic stress, J Renin Angiotensin Aldosterone Syst
Dominguez-Meijide, 2014, Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson’s disease treated with L-DOPA, Neuropharmacology, 76, 156, 10.1016/j.neuropharm.2013.07.016
Marvar, 2014, Angiotensin type 1 receptor inhibition enhances the extinction of fear memory, Biol Psychiatry, 75, 864, 10.1016/j.biopsych.2013.08.024
Linz, 2000, Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats, Hypertension, 35, 908, 10.1161/01.HYP.35.4.908
Baiardi, 2004, Angiotensin II AT1 receptor blockade prolongs the lifespan of spontaneously hypertensive rats and reduces stress-induced release of catecholamines, glucocorticoids, and vasopressin, Ann N Y Acad Sci, 1018, 131, 10.1196/annals.1296.015
Cassis, 2010, Angiotensin receptors as determinants of life span, Pflugers Arch, 459, 325, 10.1007/s00424-009-0725-4
Miyamoto, 2012, Benefits of prestroke use of angiotensin type 1 receptor blockers on ischemic stroke severity, J Stroke Cerebrovasc Dis, 21, 363, 10.1016/j.jstrokecerebrovasdis.2010.09.011
Mogi, 2012, Roles of brain angiotensin II in cognitive function and dementia, Int J Hypertens, 2012, 169649, 10.1155/2012/169649
Horiuchi, 2011, Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage, Br J Pharmacol, 163, 1122, 10.1111/j.1476-5381.2010.01167.x
Mogi, 2009, [New insights of ARB in central nervous system], Nihon Rinsho, 67, 735
Davies, 2011, Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias, J Alzheimers Dis, 26, 699, 10.3233/JAD-2011-110347
Li, 2010, Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis, BMJ, 340, b5465, 10.1136/bmj.b5465
Andrade, 2012, Do angiotensin receptor blockers really hold promise for the improvement of cognitive functioning?, Arch Intern Med, 172, 1191, 10.1001/archinternmed.2012.2091
Hajjar, 2013, Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial, J Am Geriatr Soc, 61, 194, 10.1111/jgs.12100
Kurinami, 2013, Do angiotensin receptor blockers protect against Alzheimer’s disease?, Drugs Aging, 30, 367, 10.1007/s40266-013-0071-2
Khoury, 2012, The renin-angiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms, J Clin Psychiatry, 73, 849, 10.4088/JCP.11m07316
de Cavanagh, 2006, Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine, Am J Physiol Regul Integr Comp Physiol, 290, R1616, 10.1152/ajpregu.00615.2005
Touyz, 2004, Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells, J Hypertens, 22, 1141, 10.1097/00004872-200406000-00015
Dai, 2011, Mitochondrial oxidative stress mediates induction of autophagy and hypertrophy in angiotensin-II treated mouse hearts, Autophagy, 7, 917, 10.4161/auto.7.8.15813
Kleiber, 2010, Chronic AT1 receptor blockade normalizes NMDA-mediated changes in renal sympathetic nerve activity and NR1 expression within the PVN in rats with heart failure, Am J Physiol Heart Circ Physiol, 298, H1546, 10.1152/ajpheart.01006.2009
Imaizumi, 2013, Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers, Curr Pharm Des, 19, 3002, 10.2174/1381612811319170005
Aleshin, 2013, Role of the peroxisome proliferator-activated receptors (PPAR)-α, β/δ and γ triad in regulation of reactive oxygen species signaling in brain, Biol Chem, 394, 1553, 10.1515/hsz-2013-0215
Garrido-Gil, 2012, Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson’s disease, J Neuroinflammation, 9, 38, 10.1186/1742-2094-9-38
Rong, 2010, Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice, Diabetologia, 53, 1727, 10.1007/s00125-010-1744-6
An, 2010, Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages, Hypertens Res, 33, 831, 10.1038/hr.2010.79
Benson, 2004, Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity, Hypertension, 43, 993, 10.1161/01.HYP.0000123072.34629.57
Zorad, 2006, Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma, Eur J Pharmacol, 552, 112, 10.1016/j.ejphar.2006.08.062
Rong, 2010, Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia, Br J Pharmacol, 160, 1796, 10.1111/j.1476-5381.2010.00835.x
Blessing, 2008, Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice, Atherosclerosis, 199, 295, 10.1016/j.atherosclerosis.2007.10.037
Mogi, 2008, Telmisartan prevented cognitive decline partly due to PPAR-gamma activation, Biochem Biophys Res Commun, 375, 446, 10.1016/j.bbrc.2008.08.032
Toyama, 2011, Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity, Biochem Biophys Res Commun, 410, 508, 10.1016/j.bbrc.2011.06.012
Yamagishi, 2008, Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation, Protein Pept Lett, 15, 850, 10.2174/092986608785203746
Inoue, 2000, Feedback control of cyclooxygenase-2 expression through PPARgamma, J Biol Chem, 275, 28028, 10.1074/jbc.M001387200
Straus, 2007, Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms, Trends Immunol, 28, 551, 10.1016/j.it.2007.09.003
Cianchetti, 2008, Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells, Atherosclerosis, 198, 22, 10.1016/j.atherosclerosis.2007.09.013
Nakano, 2009, Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma, Hypertens Res, 32, 765, 10.1038/hr.2009.95
Shao, 2007, Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker, J Hypertens, 25, 1643, 10.1097/HJH.0b013e328165d159
He, 2010, Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways, Hypertension, 55, 869, 10.1161/HYPERTENSIONAHA.109.143958
Li, 2013, Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation, Diabetes, 62, 762, 10.2337/db12-0570
van Rooij, 2012, MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles, Nat Rev Drug Discov, 11, 860, 10.1038/nrd3864
Reid, 2005, Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension?, J Renin Angiotensin Aldosterone Syst, 6, 15, 10.3317/jraas.2005.002
Miura, 2010, Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors, Biochem Biophys Res Commun, 391, 85, 10.1016/j.bbrc.2009.11.008
de Gasparo, 1999, The AT2 receptor: fact, fancy and fantasy, Regul Pept, 81, 11, 10.1016/S0167-0115(99)00023-3
Connolly, 2011, Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals, J Hypertens, 29, 623, 10.1097/HJH.0b013e328344a7de